Kodiak Sciences (KOD) Expected to Post Earnings on Wednesday

Kodiak Sciences (NASDAQ:KOD) is projected to release its Q2 2026 results after the market closes on Wednesday, August 12th. Analysts expect Kodiak Sciences to post earnings of ($0.9565) per share for the quarter. Investors can check the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 13, 2026 at 4:00 PM ET.

Kodiak Sciences (NASDAQ:KOD) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.94) EPS for the quarter, missing analysts’ consensus estimates of ($0.93) by ($0.01). On average, analysts expect Kodiak Sciences to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Kodiak Sciences Stock Down 0.6%

Shares of KOD stock opened at $42.62 on Wednesday. Kodiak Sciences has a twelve month low of $7.40 and a twelve month high of $47.84. The stock’s fifty day simple moving average is $37.75 and its 200 day simple moving average is $34.09. The firm has a market capitalization of $2.67 billion, a P/E ratio of -10.22 and a beta of 2.21.

Wall Street Analyst Weigh In

KOD has been the topic of several research reports. Wall Street Zen upgraded Kodiak Sciences from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. Chardan Capital upgraded shares of Kodiak Sciences from a “neutral” rating to a “buy” rating and upped their price target for the company from $14.00 to $61.00 in a research report on Monday, May 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Kodiak Sciences in a report on Friday, July 10th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Kodiak Sciences from $56.00 to $66.00 and gave the stock an “overweight” rating in a research note on Monday. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $48.14.

Institutional Investors Weigh In On Kodiak Sciences

Several large investors have recently modified their holdings of KOD. Cerity Partners LLC lifted its holdings in Kodiak Sciences by 7.4% in the fourth quarter. Cerity Partners LLC now owns 16,446 shares of the company’s stock valued at $460,000 after buying an additional 1,139 shares during the period. BNP Paribas Financial Markets raised its position in shares of Kodiak Sciences by 89.4% in the 3rd quarter. BNP Paribas Financial Markets now owns 6,373 shares of the company’s stock worth $104,000 after acquiring an additional 3,009 shares in the last quarter. Aster Capital Management DIFC Ltd acquired a new position in shares of Kodiak Sciences in the 4th quarter valued at about $119,000. Deutsche Bank AG boosted its position in shares of Kodiak Sciences by 14.9% during the 4th quarter. Deutsche Bank AG now owns 35,317 shares of the company’s stock valued at $987,000 after purchasing an additional 4,593 shares in the last quarter. Finally, American Century Companies Inc. grew its stake in Kodiak Sciences by 6.3% during the second quarter. American Century Companies Inc. now owns 79,745 shares of the company’s stock worth $297,000 after purchasing an additional 4,703 shares during the period. 89.06% of the stock is currently owned by institutional investors and hedge funds.

About Kodiak Sciences

Kodiak Sciences, Inc is a clinical‐stage biopharmaceutical company headquartered in Palo Alto, California, that focuses on the discovery and development of novel therapies for retinal diseases. The company’s proprietary technology centers on antibody biopolymer conjugates (ABCs), which are designed to extend durability, enhance tissue penetration and improve the safety profile of existing therapeutic modalities. Kodiak’s research and development efforts target conditions such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and other serious ophthalmic disorders.

The lead product candidate in Kodiak’s pipeline is KSI-301, an anti-VEGF antibody biopolymer conjugate administered via intravitreal injection.